According to David Weber, CEO of Otonomy, there are signs of heightened interest among investors in hearing science. This is good news for all of us. We take a deep dive with Otonomy’s executives into their drug pipeline, covering hearing loss and tinnitus.
This is your chance to learn all about the hearing regeneration treatment FX-322 being developed by Frequency Therapeutics. We spoke with Carl LeBel about the promising results of their Phase 1 trial, the potential benefits for tinnitus, why speech intelligibility should be the primary measure of hearing, and when the drug might reach the market.
While curing tinnitus remains a conundrum, important advances are being made in the field of hearing regeneration, which might also benefit tinnitus sufferers. The Hough Ear Institute talks about two hearing restoration treatments under development.
Do you want to know what stem cells are and how they can treat hearing loss and tinnitus? Learn all about it in this podcast! Featuring professor Marcelo Rivolta, a specialist in hearing regeneration who recently started his own biotech company.